Developing and manufacturing immunoassays and biomaterials

Our technology center located in Barcelona, Spain has vast experience in researching, developing, and manufacturing customized assays and biomaterials. Our primary focus is to develop and manufacture hemostasis immunoassay products for various Werfen platforms and biomaterials used to produce products for autoimmune diseases.

We also offer comprehensive solutions to the diagnostics market with innovative capabilities that enhance competitiveness and reduce time-to-market.

Customizing innovative solutions that reduce time to market

We provide the most innovative solutions, enhancing unique product features, and reducing time to market.

For us, continuous improvement not only applies to industrial efficiency, but also to innovation, quality, and service. This allows us to provide diagnostic solutions from the early stages of product development to product commercialization, including high-value services, such as clinical studies, worldwide registration, and on-market product support.

Bringing innovation across the healthcare ecosystem

We aim to improve patients’ quality of life, using innovation and state-of-the-art technologies to commercialize the highest-quality diagnostics products.

In parallel, we streamline the development process and assess novel biomarkers, collaborating with various stakeholders across the healthcare ecosystem.

Our partnership with global IVD companies is based on a strong commitment to quality, innovation, and operational excellence.

OEM in 2023

A challenging year, but we made progress

Despite a very challenging year, we made good progress in many different areas of the business.

Our key strategic initiative to become a reference partner in the development and supply of innovative biomaterials is trending positively. In 2023, we added 15 new biomaterials to our product portfolio.

This expansion also facilitates new assay development projects. Stemming from the completion of the development of four biomaterials, we partnered with a top five IVD company to develop two new immunoassays.

In terms of new product commercialization by our partners, we launched one new chemiluminescent assay to the Chinese market, we received 510(k) approvals for another two chemiluminescent assays, and we submitted one Class I product to the Chinese Authorities (NMPA).

Jose Luis Zarroca
Chief Operating Officer
  • 0 +

    customers using
    our solutions

  • 0

    working at OEM

  • 0

    R&D projects
    under development

2023 business highlights

Addition of 15 new biomaterials to our product portfolio

Development of two new immunoassays with a top five IVD company

Launch of new chemiluminescent assay to the Chinese market

Submission of one Class I product to the Chinese Authorities

Life at OEM

Our people in OEM

OEM Team

As our people at OEM are our most important asset, we continue investing in improving the work environment through cross-collaboration programs, and various people strategies and initiatives.

We are a diverse group of talented individuals with highly scientific backgrounds and strong customer orientation.

Our diverse and multidisciplinary teams allow us to successfully interact and collaborate with our other technology centers, and with the R&D, Quality, and Marketing departments of top IVD companies.

OEM Team

Powering Patient Care

HemosIL DDimer


HemosIL D-Dimer assays are clinically validated with cut-off values for the exclusion of venous thromboembolism (VTE), including both pulmonary embolism (PE) and deep vein thrombosis (DVT), in conjunction with a pretest probability assessment. This approach can reduce the need for costly and invasive imaging tests, typical in the diagnosis of VTE.

Learn more